Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer

By J. Soria, Yuichiro Ohe, J. Vansteenkiste, T. Reungwetwattana, B. Chewaskulyong, K. Lee, A. Dechaphunkul, F. Imamura, N. Nogami, T. Kurata and 14 more. New England Journal of Medicine, 2018

4,506 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/92d416f7d69e4e78b6e5e6039d387b6b8fcbd3af

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. M. Hellmann
2. A. Schoenfeld

Citations in the corpus

• Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer (2019, methodology): “Thus, this novel approach could be combined with traditional chemo- and targeted therapy and should have the potential to significantly improve the survival of patients with EGFR‐mutant NSCLC.”
• Mechanisms of receptor tyrosine kinase activation in cancer (2018, neutral): “Novel approaches have been shown to effectively overcome acquired resistance, including the development of second-generation [191, 192] and third-generation inhibitors [193, 194] and the combinational use of TKIs with monoclonal antibodies against the same target [195].”
• Molecular profiling for precision cancer therapies (2020, background): “the incorporation of new treatment options in patients with EGFR-mutant NSCLC (such as osimertinib) [34, 35] and BRAF-mutant NSCLC [36, 37] and melanoma (such as the dabrafenib and trametinib combination) [38], which have led to a significant improvement in survival in these patient populations and ”